Trials / Unknown
UnknownNCT05618600
Scripps-eMed Covid-19 Study: A Prospective Monitoring Study for Those Individuals Treated With Paxlovid
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 800 (estimated)
- Sponsor
- Scripps Translational Science Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A prospective monitoring study for those individuals treated with Paxlovid
Detailed description
The purpose of this study is to understand the epidemiology and pathophysiology of Paxlovid rebound in patients with acute Covid-19 infection who have been prescribed the Paxlovid per standard of care. The study will be a collaborative effort between Scripps and eMed, digitally recruiting 800 participants who have tested positive for Covid-19 and have agreed to be prescribed Paxlovid on the eMed platform. The vision of the study is to understand Paxlovid rebound and ultimately inform management of acute Covid-19 infection.
Conditions
Timeline
- Start date
- 2022-08-04
- Primary completion
- 2023-07-01
- Completion
- 2024-01-01
- First posted
- 2022-11-16
- Last updated
- 2022-11-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05618600. Inclusion in this directory is not an endorsement.